Testosterone replacement therapy in older male subjective memory complainers: Double-blind randomized crossover placebo-controlled clinical trial of physiological assessment and safety

CNS and Neurological Disorders - Drug Targets

Volumn 14, Issue 5, 2015, Pages 576-586

  Asih, Prita R ^a,b,c   Wahjoepramono, Eka J ^a,b   Aniwiyanti, Vilia ^b   Wijaya, Linda K ^a   De Ruyck, Karl ^a,c   Taddei, Kevin ^a,c   Fuller, Stephanie J ^c   Sohrabi, Hamid ^a,c   Dhaliwal, Satvinder S ^d   Verdile, Giuseppe ^c,d   Carruthers, Malcolm ^c   Martins, Ralph N ^a,c  

^a EDITH COWAN UNIVERSITY   (Australia)

^b PELITA HARAPAN UNIVERSITY   (Indonesia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d CURTIN UNIVERSITY   (Australia)

Author keywords

Aging; Alzheimer s disease; Dementia; Luteinizing hormone; Plasma; Testosterone

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN [1-40]; AMYLOID BETA PROTEIN [1-42]; ANDROSTANOLONE; APOLIPOPROTEIN E4; CHOLESTEROL; ESTRADIOL; GLUCOSE; HEMOGLOBIN; INSULIN; LUTEINIZING HORMONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; ANDROGEN; BIOLOGICAL MARKER; LIPID;

ANDROGEN THERAPY; ARTICLE; BLOOD SAMPLING; BODY FAT DISTRIBUTION; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ERYTHROCYTE COUNT; GYNECOMASTIA; HORMONE SUBSTITUTION; HUMAN; MEMORY DISORDER; RANDOMIZED CONTROLLED TRIAL; AGED; BLOOD; CEREBROSPINAL FLUID; CROSSOVER PROCEDURE; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PROCEDURES; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; ANDROGENS; BIOMARKERS; CROSS-OVER STUDIES; DIHYDROTESTOSTERONE; DOUBLE-BLIND METHOD; HORMONE REPLACEMENT THERAPY; HUMANS; LIPIDS; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS; TESTOSTERONE;

EID: 84930520226     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527314666150429112112     Document Type: Article

References (85)

1. Morley JE, Kaiser FE, Perry HM, III, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabol Clin Exp 1997; 46(4): 410-3.
2. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of A. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metabol 2001; 86(2): 724-31.
3. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metabol 2002; 87(2): 589-98.
4. Rosario ER, Chang L, Stanczyk FZ, Pike CJ. Age-related testosterone depletion and the development of Alzheimer disease. JAMA 2004; 292(12): 1431-2.
5. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol Ser A Biol Sci Med Sci 2001; 56(5): M266-72.
6. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metabol 2002; 87(11): 5001-7.
7. Schroeder ET, Zheng L, Ong MD, et al. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metabol 2004; 89(10): 4863-72.
8. Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study. J Clin Endocrinol Metabol 1996; 81(10): 3578-83.
9. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metabol 1991; 73(5): 1016-25.
10. Morley JE. Andropause, testosterone therapy, and quality of life in aging men. Cleveland Clin J Med 2000; 67(12): 880-2.
11. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metabol 2007; 92(11): 4241-7.
12. Leifke E, Gorenoi V, Wichers C, Von Zur Muhlen A, Von Buren E, Brabant G. Age-related changes of serum sex hormones, insulinlike growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin Endocrinol 2000; 53(6): 689-95.
13. Wahjoepramono EJ, Wijaya LK, Taddei K, et al. Distinct effects of testosterone on plasma and cerebrospinal fluid amyloid-beta levels. J Alzheimers Dis 2008; 15(1): 129-37.
14. Gouras GK, Xu H, Gross RS, et al. Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. Proc Natl Acad Sci USA 2000; 97(3): 1202-5.
15. Gandy S, Almeida OP, Fonte J, et al. Chemical andropause and amyloid-beta peptide. JAMA 2001; 285(17): 2195-6.
16. Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004; 29(8): 1071-81.
17. Tan RS, Pu SJ, Culberson JW. Role of androgens in mild cognitive impairment and possible interventions during andropause. Med Hypotheses 2003; 60(3): 448-52.
18. Cherrier MM, Matsumoto AM, Amory JK, et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 2005; 64(12): 2063-8.
19. Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med 2011; 124(7): 578-87.
20. Raynaud JP. Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol 2006; 102(1-5): 261-6.
21. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Lowdose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000; 102(16): 1906-11.
22. Rhoden EL, Morgentaler A. Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. Int J Impot Res 2004; 16(1): 95-7.
23. Rinnab L, Gust K, Hautmann RE, Kufer R.: Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth. Der Urol Ausg A 2009; 48(5): 516-22.
24. Feneley MR, Carruthers M. Is testosterone treatment good for the prostate? Study of safety during long-term treatment. J Sex Med 2012; 9(8): 2138-49.
25. Aaronson AJ, Morrissey RP, Nguyen CT, Willix R, Schwarz ER. Update on the safety of testosterone therapy in cardiac disease. Expert Opin Drug Safety 2011; 10(5): 697-704.
26. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metabol 1999; 84(10): 3666-72.
27. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000; 57(1): 100-5.
28. Bates KA, Harvey AR, Carruthers M, Martins RN. Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease. Cell Mol Life Sci 2005; 62(3): 281-92.
29. Bachman E, Feng R, Travison T, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metabol 2010; 95(10): 4743-7.
30. Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med 2001; 110(7): 563-72.
31. Cunningham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA 1989; 261(17): 2525-30.
32. Gooren LJ, Bunck MC. Androgen replacement therapy: present and future. Drugs 2004; 64(17): 1861-91.
33. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metabol 2000; 85(8): 2832-8.
34. Cherrier MM, Matsumoto AM, Amory JK, et al. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology 2005; 64(2): 290-6.
35. Oettel M, Hubler D, Patchev V. Selected aspects of endocrine pharmacology of the aging male. Exp Gerontol 2003; 38(1-2): 189-98.
36. Yamamoto M, Hibi H, Katsuno S, Miyake K. Serum estradiol levels in normal men and men with idiopathic infertility. Int J Urol 1995; 2(1): 44-6.
37. Carruthers M. Testosterone deficiency syndrome: cellular and molecular mechanism of action. Curr Aging Sci 2013; 6(1): 115-24.
38. Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ. Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 1988; 11(4): 247-64.
39. Fennell C, Sartorius G, Ly LP, et al. Randomized cross-over clinical trial of injectable vs implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men. Clin Endocrinol 2010; 73(1): 102-9.
40. Lista S, Faltraco F, Prvulovic D, Hampel H. Blood and plasmabased proteomic biomarker research in Alzheimer's disease. Progr Neurobiol 2013; 101-102: 1-17.
41. Henriksen K, O'Bryant SE, Hampel H, et al. The future of bloodbased biomarkers for Alzheimer's disease. Alzheimers Dement 2014; 10(1): 115-31.
42. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996; 271(51): 32916-22.
43. Mamo JC, Jian L, James AP, Flicker L, Esselmann H, Wiltfang J. Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild cognitive impairment. Ann Clin Biochem 2008; 45(Pt 4): 395-403.
44. Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007; 13(9): 1029-31.
45. Prvulovic D, Hampel H. Amyloid beta (Abeta) and phospho-tau (ptau) as diagnostic biomarkers in Alzheimer's disease. Clin Chem Lab Med 2011; 49(3): 367-74.
46. Hone E, Martins IJ, Fonte J, Martins RN. Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 2003; 5(1): 1-8.
47. Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S. No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int 2009; 55(8): 820-5.
48. Toledo JB, Shaw LM, Trojanowski JQ. Plasma amyloid beta measurements-a desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther 2013; 5(2): 8.
49. Hansson O, Zetterberg H, Vanmechelen E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 2010; 31(3): 357-67.
50. Roher AE, Esh CL, Kokjohn TA, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 2009; 5(1): 18-29.
51. Selkoe DJ, Podlisny MB, Joachim CL, et al. Beta-amyloid precursor protein of Alzheimer disease occurs as 110-to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci USA 1988; 85(19): 7341-5.
52. Huang Y, Potter R, Sigurdson W, et al. beta-amyloid dynamics in human plasma. Arch Neurol 2012; 69(12): 1591-7.
53. Gillett MJ, Martins RN, Clarnette RM, Chubb SA, Bruce DG, Yeap BB. Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. J Alzheimers Dis 2003; 5(4): 267-9.
54. Hansson O, Stomrud E, Vanmechelen E, et al. Evaluation of plasma Abeta as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. J Alzheimers Dis 2012; 28(1): 231-8.
55. Sundelof J, Giedraitis V, Irizarry MC, et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 2008; 65(2): 256-63.
56. Mayeux R, Honig LS, Tang MX, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003; 61(9): 1185-90.
57. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F. Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol 2012; 69(7): 824-31.
58. Zhou L, Chan KH, Chu LW, et al. Plasma amyloid-beta oligomers level is a biomarker for Alzheimer's disease diagnosis. Biochem Biophys Res Commun 2012; 423(4): 697-702.
59. Gupta VB, Sundaram R, Martins RN. Multiplex biomarkers in blood. Alzheimers Res Ther 2013; 5(3): 31.
60. Rosen C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease-current concepts. Mol Neurodegener 2013; 8: 20.
61. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metabol 1997; 82(2): 407-13.
62. Friedl KE, Hannan CJ, Jr., Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabol Clin Exp 1990; 39(1): 69-74.
63. Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261(8): 1165-8.
64. Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol 2001; 55(3): 315-24.
65. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metabol 2001; 86(9): 4078-88.
66. Saad F, Gooren L, Haider A, Yassin A. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 2007; 53(6): 353-7.
67. Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008; 29(1): 102-5.
68. Heiss G, Johnson NJ, Reiland S, Davis CE, Tyroler HA. The epidemiology of plasma high-density lipoprotein cholesterol levels. The Lipid Research Clinics Program Prevalence Study. Summary. Circulation 1980; 62(4 Pt 2): 16-36.
69. Glueck CJ, Gartside P, Fallat RW, Mendoza S. Effect of sex hormones on protamine inactivated and resistant postheparin plasma lipases. Metabol Clin Exp 1976; 25(6): 625-32.
70. Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973; 289(2): 72-80.
71. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metabol 2008; 93(3): 914-9.
72. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metabol 1997; 82(11): 3793-6.
73. Sih R, Morley JE, Kaiser FE, Perry HM, III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metabol 1997; 82(6): 1661-7.
74. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol Ser A Biol Sci Med Sci 2005; 60(11): 1451-7.
75. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol 2010; 95(6): 2536-59.
76. Jackson G. Late onset hypogonadism in males-think of it-act on it. Int J Clin Pract 2012; 66(2): 115-6.
77. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003; 24(3): 299-311.
78. Fowler JE, Jr., Whitmore WF, Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126(3): 372-5.
79. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol 1994; 40(3): 341-9.
80. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol 2011; 186(3): 1005-11.
81. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173(2): 533-6.
82. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004; 172(3): 920-2.
83. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24(2): 183-217.
84. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013; 11: 108.
85. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100(16): 1690-6.